Critical Reviews in Oncology / Hematology
Volume 43, Issue 2 , Pages 105-121 , August 2002

Highlights of contemporary issues in the medical management of prostate cancer

,Accepted 1 January 2002.

References 

  1. Vercelli M, Quaglia A, Marani E, Parodi S. Prostate cancer incidence and mortality trends among elderly and adult Europeans. Crit. Rev. Oncol. Hematol. 2000;35(2):133–144
  2. American Cancer Society. Prostate Cancer 2001. Ref type: Internet communication.
  3. Smith JR, Freije D, Carpten JD, et al.  Major susceptibility locus for prostate cancer on chromosome I suggested by a genome-wide search. Science. 1996;274(5291):1371–1374
  4. Walsh PC. Early stage at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC). Chromosome. 1998;1(160):265–266
  5. Tavtigian SV, Simard J, Teng DH, et al.  A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. 2001;27(2):172–180
  6. Sternberg CN. Neo-adjuvant hormonal therapy and radiation therapy in the treatment of locally advanced prostate cancer. Mol. Urol.: A Transl. Approach. 1999;3(3):227–229
  7. Pansadoro V, Sternberg C. Neo-adjuvant hormonal therapy and radical prostatectomy for locally advanced prostate cancer. Mol. Urol.: A Transl. Approach. 1999;3(3):271–275
  8. Mettlin CJ, Murphy GP, Babaian RJ, et al.  Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1997;80(9):1814–1817
  9. Chodak GW, Thisted RA, Gerber GS. Results of conservative management of clinicall localized prostate cancer. New Engl. J. Med. 1994;330:242–248
  10. Albertsen PC. Early stage prostate cancer. When is observation appropriate. Hematol. Oncol. Clin. North Am. 1996;10(3):611–625
  11. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J. Am. Med. Assoc. 1999;281(17):1591–1597
  12. Moul JW. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. Mol. Urol. 2000;4(3):267–271
  13. Carroll PR, Lee KL, Fuks ZY, Kantoff PW. Cancer of the prostate. In:  Devita VT,  Hellman S,  Rosenberg SA editor. Cancer. Philadelphia: Lippincott Williams & Wilkins; 2001;p. 1418–1479
  14. Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer. New Engl. J. Med. 1999;341(24):1837–1838
  15. Chay C, Smith DC. Adjuvant and neoadjuvant therapy in prostate cancer. Semin. Oncol. 2001;28(1):3–12
  16. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl. J. Med. 1999;341(24):1781–1788
  17. Walsh PC. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. J. Urol. 2000;164(1):264–267
  18. Schroder FH.
  19. Zincke H, Lau W, Bergstralh E, Blute ML. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J. Urol. 2001;166(6):2208–2215
  20. Zagars GK, Pollack A, von Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology. 2001;58(2):233–239
  21. Wirth M, See W, McLeod D, Iversen P, Persson B, Carroll K. Bicalutamide (‘Casodex’) 150 MG as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer. Proc. Am. Soc. Clin. Oncol. 2001;20:177a; ref type: abstract
  22. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Luprot Depot Neoadjuvant Prostate Cancer Study Group. J. Urol. 1995;154(2 Pt1):424–428
  23. Schulman CC, Debruyne FMJ, Forster G, Selvaggi FP, Zlotta AR, Witjes WPJ. 4-year follow-up results of a European Prospective Randomized Study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur. Urol. 2000;38(6):706–713
  24. Hanks GE, Corn BW, Lee WR, Hunt M, Hanlon A, Schultheiss TE. External beam irradiation of prostate cancer. Conformal treatment techniques and outcomes for the 1990s. Cancer. 1995;75(7):1972–1977
  25. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl. J. Med. 1997;337:295–300
  26. Pilepich MV, Caplan R, Byhardt R, et al.  Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group 85-31. J. Clin. Oncol. 1997;15(3):1013–1021
  27. The Canadian Uro-Oncology Group Gleave ME, Goldenberg SL, Chin JL, et al.  Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J. Urol. 2001;166(2):500–506
  28. D'Amico AV, Whittington R, Malkowicz SB, et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J. Am. Med. Assoc. 1998;280:969–974
  29. Pettaway CA, Pisters LL, Troncoso P, et al.  Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J. Clin. Oncol. 2000;18:1050–1057
  30. Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001;57(2):281–285
  31. Zelefsky MJ, Kelly WK, Scher HI, et al.  Results of a phase II study using estrmustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with advanced prostate cancer. J. Clin. Oncol. 2000;18(9):1936–1941
  32. Ben-Josef E, Porter AT, Han S, et al.  Neoadjuvant Estramustine and Etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results. Int. J. Radiat. Oncol. Biol. Phys. 2001;49(3):699–703
  33. Sternberg C. Hormone refractory metastatic prostate cancer. Ann. Oncol. 1992;3(5):331–335
  34. Scher HI, Chung LWK. Bone metastases: improving the therapeutic index. Semin. Oncol. 1994;21(5):630–656
  35. Eisenberger MA, Blumenstein BA, Crawford ED, et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl. J. Med. 1998;339(15):1036–1042
  36. Denis LJ, Carneiro de Moura JL, Bono A, et al.  Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology. 1993;42:119–130
  37. Behalf of the International Anandron Study Group Dijkman GA, Fernandez del Moral P, Debruyne FMJ, Janknegt RA. Improved subjective response to orchiectomy plus nilutamide (Anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. Eur. Urol. 1995;27(3):196–201
  38. Prostate Cancer Trialists’ Collaborative Group . Maximum adrogen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355(9214):1491–1498
  39. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: what went wrong. J. Urol. 2000;164(1):3–9
  40. Reid P, Kantoff P, Oh W. Antiandrogens in prostate cancer. Invest. New Drugs. 1999;17(3):271–284
  41. Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi Tumor Model. J. Urol. 1997;157(5):1727–1730
  42. Rambeaud JJ. Intermittent complete androgen blockade in metastatic prostate cancer. Eur. Urol. 1999;35(Suppl 1):32–36
  43. Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist. 2000;5(1):45–52
  44. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology. 2001;58(2):240–245
  45. Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur. Urol. 1998;34(Suppl 3):37–41
  46. The Abarelix Study Group Debruyne F, McLeod D, Ben-Soussen P, Campion M, Garnick MB. Abarelix depot, a pure GnRH antagonist, compared with LHRH agonist in patients with prostate cancer. Eur. Urol. 2000;37(suppl 2):128; Ref type: abstract
  47. Abarelix Depot Study Group Garnick MB, Campion M. Abarelix depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Mol. Urol. 2000;4(3):275–277
  48. McLeod D, Trachtenberg J. Abarelix depot (AD) versus leuprolide (L) with and without bicalutamide (Casodex) (C) for prostate cancer; results of two multicenter, randomized phase III studies. Eur. Urol. 2001;39(suppl 5):78; Ref type: abstract
  49. The ABACAS 1 Study Group Selvaggi F, Khoe GSS, Van Cangh P, et al.  Comparison of Abarelix depot (A-D) and Goserelin (G) plus Bicalutamide (B) in advanced prostate cancer; results of a multicentre, open-label, randomised, phase III study. Eur. Urol. 2001;39(Suppl 5):78; Ref type: abstract
  50. The Abarelix Study Group Fisher H, Barzell W, Gittelman M, et al.  Abarelix depot (A-D) monotherapy reduces PSA levels comparable to leuprolide acetate (L) plus bicalutamide (B): results of a multicenter trial of rising PSA, advanced (D1/D2), neoadjuvant hormonal therapy (NHT), and intermittant hormonal therapy (IHT) prostate cancer (PC) patients (Pts.). Proc. Am. Soc. Clin. Oncol. 2001;20:152b; Ref type: abstract
  51. Scher HI, Sternberg CN. Chemotherapy of urologic malignancies. Semin. Urol. 1985;3:239–280
  52. Collette L, Fossa SD, Oosterhof GON, et al.  Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of ‘good prognosis’ metastatic hormone refractory prostate cancer patients. Eur. J. Cancer. 2001;37(Suppl 6):S218; Ref type: abstract
  53. Kelly WK, Osman I, Reuter VE, et al.  The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clin. Cancer Res. 2000;6(3):838–846
  54. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J. Clin. Oncol. 1993;11(4):607–615
  55. Small EJ, McMillan A, Meyer M, et al.  Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J. Clin. Oncol. 2001;19(5):1304–1311
  56. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J. Clin. Oncol. 1998;16:1835–1837
  57. Bubley GJ, Carducci M, Dawson N, et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J. Clin. Oncol. 1999;17(11):3461–3467
  58. Dawson NA, Vogelzang NJ. In:  Resnick MI,  Thompson IM editor. Secondary hormonal therapy in advanced therapy of prostate disease. Ontario: BC Decker Inc Hamilton; 2000;p. 378–384
  59. Scher HI, Kelly WK. The flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostatic cancer. J. Clin. Oncol. 1993;11:1566–1572
  60. Culig Z, Hoffmann J, Erdel M, et al.  Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a New Model System. Br. J. Cancer. 1999;81(2):242–251
  61. Blackledge GR. High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology (Supp). 1996;47(1A):44–47
  62. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J. Urol. 1997;157(4):1204–1207
  63. Small EJ, Halabi S, Picus J, Dawson N, Chen Y, Vogelzang NJ. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in adrogen independent prostate cancer patients: results of CALGB 9583. Proc. Am. Soc. Clin. Oncol. 2001;20:174a; ref type: abstract
  64. Sella A, Kilbourn R, Amato R, et al.  Phase II study of ketaconazole combined with weekly doxorubicin in patients with androgen-indipendent prostate cancer. J. Clin. Oncol. 1994;12(4):683–688
  65. Darzynkiewicz Z, Traganos F, Wu JM, Chen S. Chinese herbal mixture PC SPES in treatment of prostate cancer (review). Int. J. Oncol. 2000;17(4):729–736
  66. DiPaola RS, Zhang H, Lambert GH, et al.  Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. New Engl. J. Med. 1998;339(12):785–791
  67. Small EJ, Frohlich MW, Bok R, et al.  Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J. Clin. Oncol. 2000;18(21):3595–3603
  68. Konyves I, Muntzing J. Ten year experience with estramustine phosphate in the treatment of prostatic carcinoma. In: New trends in diagnosis and treatment of prostatic cancer. Rome: Acta Medica SpA; 1987;p. 210–218
  69. Hartley-Asp B, Natale RB, Dreicer R, et al.  Phase II study of weekly intravenous (IV) estramustine phosphate (EMP IV) 2000 mg/m2 in patients with hormone-refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 2001;20:183a; ref type: abstract
  70. Hudes GR, Greenberg R, Krigel RL, et al.  Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol. 1992;10:1754–1761
  71. Seidman AD, Scher HI, Petrylak D, Dershaw D, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial endpoint in hormone-refractory prostatic cancer. J. Urol. 1992;147:931–934
  72. Hudes G, Einhorn L, Ross E, et al.  Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a hoosier oncology group and Fox Chase Network Phase III trial. J. Clin. Oncol. 1999;17(10):3160–3166
  73. Albrecht W, Horenblas S, Marechal JM, et al.  A randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped progressive metastatic prostate cancer. Eur. Urol. 1998;33(S1):47; Abstract 187
  74. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J. Clin. Oncol. 1985;3:827–841
  75. Osborne CK, Drelichman A, Von Hoff DD, Crawford ED. Mitoxantrone: modest activity in a Phase II trial in advanced prostate cancer. Cancer Treat. Rep. 1983;67:1133–1135
  76. Kantoff PW, Block C, Letvak L, George M. 14-day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate. Am. J. Clin. Oncol. 1993;16:489–491
  77. Moore MJ, Osoba D, Murphy K, et al.  Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J. Clin. Oncol. 1994;12:689–694
  78. Tannock IF, Osoba D, Stochler MR, et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end-points. J. Clin. Oncol. 1996;14(6):1756–1764
  79. Kantoff PW, Halabi S, Conaway M, et al.  Hydrocortisone with or without mitoxantrone in men with with hormone refractory prostate cancer: results of cancer and leukemia group B 9182 study. J. Clin. Oncol. 1999;17:2506–2513
  80. Picus J, Schultz M. Docetaxel (taxotere) as a monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin. Oncol. 1999;26(5 Suppl 17):14–18
  81. Trivedi C, Redman B, Flaherty LE, et al.  Weekly 1-h infusion of clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer. 2000;89(2):431–436
  82. Friedland D, Cohen J, Miller Jr R. A phase II trial of docetaxel (taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin. Oncol. 1999;26(5 Suppl 17):19–23
  83. Rohrbaugh T, Berry W. Phase II trial of single-agent, weekly (wk) taxotere [trade] (T) in symptomatic, hormone-refractory prostate cancer (HRPC), Proc Annu Meet Am Soc Clin Oncol 1999;18. ref type: abstract.
  84. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel (taxotere) in hormone refractory metastatic prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 2000;19:348a; ref type: abstract
  85. Gravis G, Bladou F, Salem N, et al.  Efficacy, quality of life (QOL) and tolerance with weekly docetaxel (D) in metastatic hormone refractory prostate cancer (HRPC) patients. Proc. Annu. Meet Am. Soc. Clin. Oncol. 2001;20:171b; ref type: abstract
  86. Scholz MC, Guess B, Barrios F, Strum S, Leibowitz R. Low-dose single-agent weekly docetaxel (taxotere) is effective and well tolerated in elderly men with prostate cancer. Proc. Annu. Meet Am. Soc. Clin. Oncol. 2001;20:173b; ref type: abstract
  87. Hudes GR, Nathan F, Khater C, et al.  Phase II trial of 96 h paclitaxel plus oral estramustine phosphate in metastatic hormone refractory. J. Clin. Oncol. 1997;15(9):3156–3163
  88. Kosty MP, Ferreira A, Bryntesen T. Weekly docetaxel and low-dose estramustine phosphate in hormone refractory prostate cancer: a phase II study. Proc. Annu. Meet Am. Soc. Clin. Oncol. 2001;20:152b; ref type: abstract
  89. Rajasenan KK, Friedland DM, Lembersky BC, Pinkerton RA, Voloshin MD, Freeman PF. Weekly docetaxel alone or with estramustine has significant activity in patients with hormone-refractory prostate cancer previously treated with conventionally dosed docetaxel. Proc. Annu. Meet Am. Soc. Clin. Oncol. 2001;20:171b; ref type: abstract
  90. Natale R, Zaretsky S. Phase I/II trial of estramustine (E) and taxotere (T) in patients with metastatic hormone-refractory prostate cancer (HRPC), Proc Annu Meet Am Soc Clin Oncol 2002;18. ref type: abstract.
  91. Copur MS, Tarantolo SR, Hauke R, et al.  Weekly estramustine (E) Taxotere (T) and dexamthasone (D) in patients with hormone refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 2000;19:347a; ref type: abstract
  92. Smith CD, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J. Clin. Oncol. 1999;17(6):1664–1671
  93. Pienta KJ, Redman BG, Bandekar R, et al.  A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology. 1997;50(3):401–406
  94. Dimopoulos MA, Panopoulos C, Barnia C, et al.  Oral estramustine and oral etoposide for hormone refractory prostate cancer. Urology. 1997;50(5):754–758
  95. Pienta KJ, Fisher EI, Eisenberger MA, et al.  A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: a Southwest Oncology Group Trial (SWOG 9407). Prostate. 2001;46(4):257–261
  96. Petrylak DP, MacArthur RB, O'Connor J, et al.  Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol. 1999;17(3):958–967
  97. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann. Oncol. 1999;10(1):33–38
  98. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M Eisenberger MA. John Hopkins University, Baltimore MD. A phase II study evaluating docetaxel (D) and one day of estramustine phosphate (EMP) in patients (pts) with hormone refractory prostate cancer (HRPC): updated preliminary analysis, Proc Am Soc Clin Oncol 2000;19:346a. Ref type: abstract.
  99. Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N. A phase II study of docetaxel (taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B trial 9780. Semin. Oncol. 1999;26(5 Suppl 17):39–44
  100. Leitner SP, Scoppetuelo M, Kanowitz JM, Lowry PA, Clyde J. Phase II trial of weekly one hour Paclitaxel (T) plus oral Estramustine (E) taken the day before, of, and after Paclitaxel in patients (Pts) with metastatic hormone refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 1999;18:345a; ref type: abstract
  101. Hudes GR, Manola J, Conroy J, Habermann T, Wilding G. Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced-dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma (HRPC): a trial of the Eastern Cooperative Oncology Group. Proc. Am. Soc. Clin. Oncol. 2001;20:175a; ref type: abstract
  102. Berry W, Gregurich M, Dakhil S, Hathorn J, Asmar L. Phase II randomized trial of weekly paclitaxel (taxol) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate (HRMCP). Proc. Am. Soc. Clin. Oncol. 2001;20:175a; ref type: abstract
  103. Kelly WK, Curley T, Slovin S, et al.  Paclitaxel (T), estramustine (E) and carboplatin (Cc) in patients with advanced prostate cancer. J. Clin. Oncol. 2001;19(1):44–53
  104. Tyrrell C, Bullard S, Barber J, Graham J. Open-label phase II study of ZD0473 in patients with metastatic hormone refractory prostate cancer. Eur. J. Cancer. 2001;37(Suppl 6):S222; ref type: abstract
  105. Small EJ, Meyer M, Marshall ME, et al.  Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J. Clin. Oncol. 2000;18(7):1440–1450
  106. Logothetis CJ, Hoosein NM, Hsieh JT, et al.  The clinical and biological study of androgen independent prostate cancer (AIPCa). Semin. Oncol. 1994;21(5):620–629
  107. Ferrer FA, Rodriguez R. Prostate cancer gene therapy. Hematol. Oncol. Clin. North Am. 2001;15(3):497–508
  108. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostete-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57(13):2559–2563
  109. Gleave ME, Miyake H, Nelson C, Rennie P, Leung S. Targeting antiapoptotic genes upregulated by androgen withdrawal using antisense oligodeoxynucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. In:  Chung L,  Isaacs WB,  Simons JW editor. Prostate cancer. Totowa, NJ: Humana Press; 2001;p. 327–340
  110. Simons JW, Mikhak B, Chang JF, et al.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte–macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999;59(20):5160–5168
  111. Rodriguez R. Gene Manipulation in Medicine and Gene Therapy. AUA Course #H0034 PG. J. Urol. 2001;165:XXI.
  112. Small EJ, Carducci MA, Wilding G. A phase I/II dose finding trial of the intravenous injection of CV787, a prostate specific antigen-dependent cytolytic adenovirus in patients with advanced hormone refractory prostate cancer (HRPC). Eur. J. Cancer. 2001;37(Suppl. 6):S217; ref type: abstract
  113. Scaduto AA, Lieberman JR. Gene therapy for osteoinduction. Orthop. Clin. North Am. 1999;30(4):625–633
  114. Lim H, Camacho N, Schurr E, Henderson D, Simons J, Rodriguez R. Diphtheria toxin as a cytotoxic cDNA for in vivo gene therapy of prostate cancer. Meet Am. Assoc. Cancer Res. 1997;38:A2560; ref type: abstract
  115. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19(56):6550–6565
  116. Saltz L, Rubin M, Hochster H, et al.  Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 2001;20:3a; ref type: abstract
  117. Augus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/Neu As a Therapeutic Target in Non-Small Cell Lung Cancer, Prostate Cancer, and Ovarian Cancer. Semin. Oncol. 2000;27(6 Suppl 11):53–63
  118. Barton J, Blackledge G, Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy(1). Urology. 2001;58(2 Suppl):114–122
  119. Jansen B, Wacheck V, Heere-Ress E, et al.  Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet. 2000;356(9243):1728–1733
  120. Tamm I, Dorken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea. Lancet. 2001;358(9280):489–497
  121. Morris MJ, Tong WP, Cordon-Cardo C, et al.  BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer. Eur. J. Cancer. 2001;37(Suppl. 6):S218; ref type: abstract
  122. Tolcher AW. Preliminary phase I results of G3139 (Bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin. Oncol. 2001;28(4 Suppl 15):67–70
  123. Chi KN, Gleave ME, Klasa R, et al.  A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. 2001;7(12):3920–3927
  124. Goluboff ET. Exisulind, a selective apoptotic antineoplastic drug. Expert Opin. Invest. Drugs. 2001;10(10):1875–1882
  125. UCLA Oncology Research Network Goluboff ET, Prager D, Rukstalis D, et al.  Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J. Urol. 2001;166(3):882–886
  126. Ryan CW, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. Semin. Oncol. 2001;28(4 Suppl 15):56–61
  127. Johnson CS, Yu WD, Modzelewski RA, et al.  The effect of 1,25-dihydroxyvitamin D (calcitriol) on carboplatin-mediated antitumor activity: preclinical and clinical studies. Proc. Annu. Meet Am. Soc. Clin. Oncol. 1999;18:216a; ref type: abstract
  128. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin. Cancer Res. 1999;5(6):1339–1345
  129. Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. J. Urol. 2000;163(1):187–190
  130. Major P, Lortholary A, Hon J, et al.  Zoledronic acid is superior to pamidronate in the treeatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 2001;19(2):558–567
  131. Tolcher AW, Kennedy A, Padley RJ, Majeed N, Pollak M, Kantoff PW. Other novel agents: rationale and current status as chemopreventive agents. Urology. 2001;57(4 Suppl 1):86–89
  132. Singh A, Padley RJ, Ashraf T. The selective endothelin-a receptor antagonist improves quality of life (QOL) weighted time to progression in hormone refractory prostate cancer patients. Eur. J. Cancer. 2001;37(Suppl. 6):S220; ref type: abstract
  133. Kuban DA, Delbridge T, El-Mahdi AM, Schellhammer PF. Halfbody irradiation for treatment of widely metastatic carcinoma of the prostate. J. Urol. 1989;141:572–574
  134. Porter AT, McEwan AJB, Powe JE, et al.  Results of a randomized phase III trial to evaluate the efficacy of Strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1993;25:805–813
  135. Babaian RJ, Sayer J, Podoloff DA, Steelhammer LC, Bhadkamkat VA, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with 111-indium labeld monoclonal antibody CYT-356. J. Urol. 1994;152:1952–1955
  136. Tu SM, Millikan RE, Mengistu B, et al.  J. bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357(9253):326–327
  137. Smith MR, McGovern FJ, Fallon M, Schoenfeld DA, Kantoff PW, Finkelstein JS. Randomized prospective study of pamidronate for prevention of bone loss in men undergoing hormonal therapy for prostate cancer. Proc. Am. Soc. Clin. Oncol. 2001;20:175a; ref type: abstract
  138. Dearnaley DP, Sydes MR. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pr05 trial. Proc. Am. Soc. Clin. Oncol. 2001;20:174a; ref type: abstract
  139. Hamdy NA, Papapoulos SE. The palliative management of skeletal metasteses in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin. Nuclear Med. 2001;31(1):62–68
  140. Olson KB, Pienta KJ. Use of bisphosphonates in the treatment of prostate cancer. Oncology (Huntingt). 2000;14(9):1361–1364
  141. Roth B, Yeap B, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. a phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;15; 72(8):2457–2460
  142. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J. Clin. Oncol. 1999;17:1664–1671

PII: S1040-8428(02)00023-9

Critical Reviews in Oncology / Hematology
Volume 43, Issue 2 , Pages 105-121 , August 2002

Article Tools